Intraperitoneal infusion of recombinant interleukin-2 in malignant ascites in patients with gastrointestinal and ovarian cancer.

S. Bertoglio, G. Melioli, E. Baldini, A. Catturich, M. R. Sertoli, D. Civalleri, P. Percivale, W. Meier, A. Galazka, F. Badellino

Research output: Contribution to journalArticlepeer-review

Abstract

In a phase-I-study recombinant interleukin-2 (rIL-2) in a dose from 0.01 to 0.3 mg/m2/day for 7 to 14 days was infused intraperitoneally. Side effects were fever and fluid retention. 2 patients showed a bacterial peritonitis after paracentesis. The investigations showed that the intraperitoneal (i.p.) administration of interleukin-2 activates the whole lymphokine cascade.

Original languageEnglish
Pages (from-to)81-83
Number of pages3
JournalActa Medica Austriaca
Volume16
Issue number3-4
Publication statusPublished - Dec 1 1989

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Intraperitoneal infusion of recombinant interleukin-2 in malignant ascites in patients with gastrointestinal and ovarian cancer.'. Together they form a unique fingerprint.

Cite this